Scholar Rock Holding Corp
Company Profile
Business description
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Contact
301 Binney Street
3rd Floor
CambridgeMA02142
USAT: +1 857 259-3860
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
289
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,450.00 | 38.70 | 0.41% |
| CAC 40 | 8,699.71 | 30.42 | 0.35% |
| DAX 40 | 26,140.13 | 13.83 | 0.05% |
| Dow JONES (US) | 53,885.10 | 464.02 | -0.85% |
| FTSE 100 | 10,867.89 | 20.41 | -0.19% |
| HKSE | 25,567.85 | 37.57 | 0.15% |
| NASDAQ | 26,348.35 | 15.09 | -0.06% |
| Nikkei 225 | 65,341.80 | 341.46 | -0.52% |
| NZX 50 Index | 13,868.89 | 89.17 | -0.64% |
| S&P 500 | 7,709.96 | 13.59 | -0.18% |
| S&P/ASX 200 | 9,269.30 | 40.50 | 0.44% |
| SSE Composite Index | 3,919.51 | 19.16 | 0.49% |